Concerning the molecular requirements for the inhibition of the uptake of racemic  3 H-norepinephrine into rat cerebral cortex slices by tricyclic antidepressants and related compounds.
D000475:Alkenes / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001011:Aorta / Q000378:metabolism; D001567:Benzocycloheptenes / Q000494:pharmacology*; D001593:Benzyl Compounds / Q000494:pharmacology; D001693:Biological Transport, Active; D002227:Carbazoles / Q000494:pharmacology; D002540:Cerebral Cortex / Q000378:metabolism*; D003864:Depression, Chemical; D003984:Dibenzazepines / Q000494:pharmacology*; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D009638:Norepinephrine / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D014316:Tritium
D000475:Alkenes; D000928:Antidepressive Agents; D001567:Benzocycloheptenes; D001593:Benzyl Compounds; D002227:Carbazoles; D003984:Dibenzazepines; D014316:Tritium; D009638:Norepinephrine